Results 161 to 170 of about 30,449 (250)

Clinical Application of a Neonatal Delirium Screening Tool: A Feasibility Study

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aims The aims were as follows: (1) to adapt the Sophia Observation withdrawal Symptoms—Paediatric Delirium (SOS‐PD) screening tool for use in neonates (SOS‐ND), (2) to estimate the accuracy of SOS‐ND (used by nurses) compared to assessment by a child psychiatrist using an adapted version of Vanderbilt Assessment of Delirium in Infants and ...
Rikke Louise Stenkjaer   +7 more
wiley   +1 more source

Developmental Osteopenia: An Explanation for Fractures in Young Infants

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim The aim is to test whether a fraction of full‐term infants pass through a phase of postnatal fracture susceptibility and whether this physiological phase explains real‐world fracture age distributions in young infants. Methods Preterm infant data were used to establish fracture risk zones based on bone quality (using Speed of Sound, SOS ...
Chris Brook, Julie Mack, Waney Squier
wiley   +1 more source

Phagosomal granulocytic ROS in septic patients induce the bacterial SOS response. [PDF]

open access: yesiScience
Chollet S   +9 more
europepmc   +1 more source

Transformation of the Agrarian Landscape and Hope in the Central Kalimantan Peatlands

open access: yesAsia Pacific Viewpoint, EarlyView.
ABSTRACT In Kalimantan, Indonesian Borneo, agrarian state programs and corporate strategies seek to transform indigenous Ngaju Dayak into sedentary farmers. Focusing on the notion of transformation, the paper traces whether and how rural people can engage in struggles against structural injustices.
Anu Lounela
wiley   +1 more source

LexA, an SOS response repressor, activates TGase synthesis in <i>Streptomyces mobaraensis</i>. [PDF]

open access: yesFront Microbiol
Shi X   +9 more
europepmc   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe   +4 more
wiley   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

open access: yesCancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy